Skip to main content
. 2023 Feb 11;198(2):361–368. doi: 10.1007/s10549-023-06871-w

Table 2.

Breast cancer mortality risk based on exposure to estrogen therapy

Cases N (%) Controls N (%) Crude OR (95% CI) Adjusted * OR (95% CI) Adjusted** OR (95% CI)
No estrogen therapy 1103 (87.4) 10,850 (86.0) 1 1 1
Estrogen therapy concurrent with AI 48 (3.8) 404 (3.2) 1.17 (0.86–1.58) 0.84 (0.61–1.16) 0.87 (0.62–1.22)
Estrogen therapy concurrent with tamoxifen 44 (3.5) 287 (2.3) 1.50 (1.09–2.08) 1.26 (0.89–1.79) 1.30 (0.91–1.86)
Estrogen therapy concurrent with both AI and tamoxifen as sequential therapy 29 (2.3) 230 (1.8) 1.23 (0.83–1.83) 1.10 (0.73–1.67) 1.14 (0.74–1.74)
Estrogen therapy without concurrent AI or tamoxifen 38 (3.0) 849 (6.7) 0.44 (0.31–0.61) 0.61 (0.43–0.86) 0.61 (0.43–0.87)

OR odds ratio, CI confidence interval

*Adjusted for age, time from breast cancer diagnosis to index date, T stage, N stage, and chemotherapy

**Adjusted for variables in previous adjustment*, as well as educational level, family income, marital status, CCI, DCI, previous estrogen therapy exposure, region

HHS Vulnerability Disclosure